XML 61 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1

Equity (Tables)

12 Months Ended

Dec. 31, 2023

Summary of Stock Option Activity

A summary of the status of the options granted by Teva as of December 31, 2023, 2022 and 2021, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof).

		Year ended December 31,
		2023								2022								2021
		Number (in thousands)				Weighted average exercise price				Number (in thousands)				Weighted average exercise price				Number (in thousands)				Weighted average exercise price
Balance outstanding at beginning of year			24,119			$	36.83				29,015			$	36.96				35,234			$	37.27
Changes during the year:
Forfeited			(885	)			34.65				(2,378	)			33.77				(3,644	)			36.09
Expired			(531	)			37.57				(2,518	)			41.26				(2,575	)			42.40
Balance outstanding at end of year			22,703				36.89				24,119				36.83				29,015				36.96
Balance exercisable at end of year			22,703				36.89				24,119				36.83				26,989				38.30

No options were granted during 2023, 2022 and 2021.

Schedule of Ordinary Shares Issued Upon Vested Options

The following table summarizes information as of December 31, 2023 regarding the number of ordinary shares issuable upon vested options:

Number of ordinary shares issuable upon exercise of vested options
Range of exercise prices		Balance at end of period (in thousands)				Weighted average exercise price				Weighted average remaining life
		Number of shares				$				Years
Lower than $15.01			592				11.40				3.84
$15.01 - $25.00			7,374				18.95				4.14
$25.01 - $35.00			5,470				34.66				3.17
$35.01 - $45.00			61				37.97				2.78
$45.01 - $55.00			5,707				51.26				1.36
$55.01 - $65.00			3,500				59.04				1.34
Total			22,703				36.89				2.76

Schedule of the Number of RSUs Issued and Outstanding

The following table summarizes information about the number of RSUs and PSUs granted and outstanding:

		Year ended December 31,
		2023								2022								2021
		Number (in thousands)				Weighted average grant date fair value				Number (in thousands)				Weighted average grant date fair value				Number (in thousands)				Weighted average grant date fair value
Balance outstanding at beginning of year			32,302			$	9.11				24,412			$	11.58				20,720			$	13.81
Granted			16,608				9.77				18,755				7.42				12,748				10.42
Vested			(10,195	)			10.28				(7,571	)			13.02				(6,818	)			15.60
Forfeited			(3,052	)			9.81				(3,293	)			9.81				(2,238	)			12.18
Balance outstanding at end of year			35,664				9.07				32,302				9.11				24,412				11.58

Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value

The Company expenses compensation costs are based on the grant-date fair value. For the years ended December 31, 2023, 2022 and 2021, the Company recorded stock-based compensation costs as follows:

		Year ended December 31,
		2023				2022				2021
		(U.S. $ in millions)
Employee stock options		$	—			$	2			$	16
RSUs and PSUs			121				122				103
Total stock-based compensation expense			121				124				119
Tax effect on stock-based compensation expense			11				9				12
Net effect		$	110			$	115			$	107

Accumulated Other Comprehensive Income/(Loss) (Net of Tax)

The components of accumulated other comprehensive loss attributable to Teva are presented in the table below:

		Net Unrealized Gains/(Losses)								Benefit Plans
		Foreign currency translation adjustments				Derivative financial instruments				Actuarial gains/(losses) and prior service (costs)/ credits				Total
		(U.S. $ in millions)
Balance as of January 1, 2021		$	(1,919	)			(363	)			(117	)			(2,399	)
Other comprehensive income/(loss) before reclassifications			(386	)			—				18				(368	)
Amounts reclassified to the statements of income			—				39				18				57
Net other comprehensive income/(loss) before tax			(386	)			39				36				(311	)
Corresponding income tax			31				—				(4	)			27
Net other comprehensive income/(loss) after tax*			(355	)			39				32				(284	)
Balance as of December 31, 2021			(2,274	)			(324	)			(85	)			(2,683	)
Other comprehensive income/(loss) before reclassifications			(223	)			—				40				(183	)
Amounts reclassified to the statements of income			—				29				27				56
Net other comprehensive income/(loss) before tax			(223	)			29				67				(127	)
Corresponding income tax			(17	)			—				(10	)			(27	)
Net other comprehensive income/(loss) after tax*			(240	)			29				57				(154	)
Balance as of December 31, 2022			(2,514	)			(295	)			(28	)			(2,838	)
Other comprehensive income/(loss) before reclassifications			167				(1	)			(17	)			149
Amounts reclassified to the statements of income			—				30				(4	)			26
Net other comprehensive income/(loss) before tax			167				29				(21	)			175
Corresponding income tax			(37	)			—				3				(34	)
Net other comprehensive income/(loss) after tax*			130				29				(18	)			141
Balance as of December 31, 2023		$	(2,384	)		$	(266	)		$	(46	)		$	(2,697	)

* Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $50 million loss in 2023, $116 million loss in 2022 and $107 million loss in 2021.

X

- Definition

Tabular disclosure of share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the components of accumulated other comprehensive income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481674/830-30-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-20

+ Details

Name:	us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Subparagraph (e)(2)
-Name Accounting Standards Codification
-Paragraph 2
-Section 50
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration